Skip to main content
Paul Strouts

Paul Strouts

CEO of Life Sciences at Acacium Group; oversees Proclinical, R&D Partners, and DRA across 250 staff in 12 countries

Jun 2, 2026

57:24
Yeah, what, how do you see the next couple of years in our industry? What do you think is gonna change?
57:28
Yeah, I do, and I, and I've listened to a few, few of your previous podcast and, um, yeah, and some, some people I, I would go as far as to say have been, been a little bit dismissive o-of AI, um, thinking it won't, it won't do too much and, you know, may-maybe it's a little bit an unnecessary noise at the moment.
57:45
Uh, I, I'm, I'm a, I'm a little different to that.
57:48
I think it will affect our industry.
57:50
I think it's already, uh, affecting the kind of the clinical trial process, for example.
57:55
So if we're gonna affect that, getting drugs to market quicker, it can certainly affect recruitment.
58:00
I think that, you know, we, we are doing lots of things at the moment, you know, within, within, within the case in life sciences, kind of got an in-house AI tool.
62:41
So my final question is, what are you aiming for? What's the goal for you? Where are you heading? What's the end game?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.